Ruthenium nitrosyl complex on prevention of feto-placentary and systemic change in gestational disease: potential use in preeclampsia

Diabetes and gestational hypothyroidism, as well as reduced nitric oxide (NO) bioavailability and increased vasoconstrictors, which are responsible for systemic hypertension and cardiovascular and fetal impairment1. Thus, due to the great biological importance of NO and considering that many diseases are associated with NO deficiency, prodrugs are based on metal complexes are synthesized in order to develop nitric oxide donor agents2. Ruthenium nitrosyl complex like [Ru(NH.NHq)(tpy)NO]3+ (RuNO) have been demonstrated promising results as hypotensive3. In this work we will demonstrate the therapeutic potential of the RuNO prevention of gestational and systemic changes in gestational hypothyroid rats by assessing fetal-placental development. Hypothyroid pregnant rats were treated with RuNO from the 8° day of gestation, the results demonstrated a higher fetal weight after 14 days of gestation (P<0.05) as well as the uterus+placenta group. The activation of Grp 78 and Chopp genes by RuNO treatment exhibit the re-establishment of UPR (unlfold protein response) placenta.